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Background
According to the World Health Organization, 40% of the world’s 
population have sensitivity to allergies and this number is only climbing. 
Existing treatments are only able to mitigate symptoms after an immune 
response has already occurred creating a potential to develop new 
treatment options for allergies by preventing this response from 
occurring.
Mast cells are the primary biological executors of the allergic response, 
and they are responsible for releasing inflammatory molecules into the 
bloodstream in response to an allergen being present in the body in a 
process called degranulation. These are generally responsible for 
common allergic symptoms like itchiness, runny nose, sneezing, and dry 
throat that have become hallmarks of the allergic response. By inhibiting 
molecules in this pathway and thus preventing degranulation from 
occurring, we hope to shine light on an alternative, preferred method of 
allergy treatment for the millions of people afflicted with them every day.
Current ResultsInhibitors
● DMS - competitive inhibitor of SK (Sphingosine Kinase), previously 
tested in tested in leukemia, fibroblasts, and pheochromocytoma cells
● JTE013 - antagonist of S1P2 (Sphingosine-1-Phosphate Receptor-2), 
shown to possibly alter histamine release or mast cell degranulation.
● IC84114: selective PI3K (Phosphoinositide 3-kinase) p110δ inhibitor was 




 Future Research Goals
● Repetition of assay using a more concentrations 
on the lower end of the range to develop a linear fit 
for standard curve.
● Continue culturing MC9 and RBL-2H3 cell cultures 
● Conduct ELISA assay on both cell lines to find 
optimal degranulation 
● Introduce inhibitors and measure any changes in 
degranulation
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Figure 2.  Overview of 
antigen-IgE mediated 


















Figure 4. Beta-hexosaminidase (beta-hex) is found in mast 
cell granules and its release can be used to measure the 
amount of degranulation. In the positive control, we added 
varying concentrations (0-250 ng) of beta-hex to 1.5 mg/mL 
pNAG substrate in citrate buffer to determine the upper limit 
of detection by this assay. This positive control resulted in a 
linear standard curve in the concentration ranges between 0 
and 100 ng, so we will be testing in this concentration range 
for future assays.
Figure 3. Signaling pathway 
in mast cells resulting in 
degranulation, highlighting 
small molecules of interest
● SHIP1 - SHIP1 inhibits 
immune receptor 
signaling through 





Can we inhibit the release of chemical mediators from mast cells via 
degranulation and disrupt the allergic response by use of inhibitors?
 
Hypothesis: If known inhibitors of small molecules in the mast cell 
signaling pathway are applied to mast cell culture, then degranulation will 
be reduced in vitro. 
Cell Cultures
● Mast cells are cells filled with allergic mediator granules that are found 
in connective tissue and release histamine and other substances 
during inflammatory and allergic reactions.
● Basophils are circulating white blood cells that function similarly to 
mast cells. We selected MC9 mouse mast cells and RBL-2H3 basophil 
cells to model the immune response. 
Determine level of degranulation in mast cells
